within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AF04_Betrixaban;

model Betrixaban
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.34,
    Cl = 9.555555555555556e-07,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.032799999999999996,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005833333333333334,
    Tlag = 30.0,
    Vdp = 0.016800000000000002,
    k12 = 2.0000000000000003e-06,
    k21 = 2.0000000000000003e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Betrixaban</td></tr><tr><td>ATC code:</td><td>B01AF04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>32.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.44</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Betrixaban is an oral, direct, selective inhibitor of factor Xa used as an anticoagulant to reduce the risk of venous thromboembolism (VTE) in adult patients. It has been approved for this indication in certain regions but is not widely marketed today, as the manufacturer discontinued its sale in recent years.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Dunois, C (2021). Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). <i>Biomedicines</i> 9(5) –. DOI:<a href=\"https://doi.org/10.3390/biomedicines9050445\">10.3390/biomedicines9050445</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33919121/\">https://pubmed.ncbi.nlm.nih.gov/33919121</a></p></li><li><p>Lekura, J, &amp; Kalus, JS (2018). Overview of betrixaban and its role in clinical practice. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 75(15) 1095–1102. DOI:<a href=\"https://doi.org/10.2146/ajhp170785\">10.2146/ajhp170785</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29941506/\">https://pubmed.ncbi.nlm.nih.gov/29941506</a></p></li><li><p>Huisman, MV, &amp; Klok, FA (2018). Pharmacological properties of betrixaban. <i>European heart journal supplements : journal of the European Society of Cardiology</i> 20(Suppl E) E12–E15. DOI:<a href=\"https://doi.org/10.1093/eurheartj/suy016\">10.1093/eurheartj/suy016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29977164/\">https://pubmed.ncbi.nlm.nih.gov/29977164</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AF04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Betrixaban;
